# Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

> **NCT06533761** · PHASE1 · RECRUITING · sponsor: **Stelexis BioSciences** · enrollment: 125 (estimated)

## Conditions studied

- AML, Adult
- MDS

## Interventions

- **DRUG:** Eganelisib
- **DRUG:** Eganelisib in combination with cytarabine

## Key facts

- **NCT ID:** NCT06533761
- **Lead sponsor:** Stelexis BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2027-07-15
- **Final completion:** 2028-03-15
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06533761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06533761, "Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06533761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*